Joshua Schultz has been appointed chief executive officer, Cytel Inc. He succeeds Joseph Avellone, who acted as Cytel’s interim chief executive and will continue to serve on the company’s board.
Mr. Schultz has a 20-year track record of success in life sciences and clinical research organizations. He joins Cytel from PAREXEL, where he most recently served as an officer of the company and senior vice president for its Access business unit.  

Cyrus Mehta, co-founder of Cytel said, “As a recognized pioneer in advanced analytics, Cytel is in a very strong position today. We are delighted to have found a high-caliber leader in Joshua Schultz to take us forward into the next chapter of growth for the company. Along with an exceptional commercial track record, Joshua shares the commitment to technological innovation, talent development, and cutting edge research that shaped Cytel’s history. Therefore, we are confident that under his leadership we will further enhance the value we deliver to our customers, employees, and the life science industry as a whole.”

Mr. Schultz has built and led groups for services spanning the development lifecycle, including study-start up, late phase trials, and market access. His achievements include the development of novel approaches to building high-value strategic partnerships with life science companies and creating innovative operational models that leverage real-world data and related technologies.